Phosphatase PP2A is requisite for the function of regulatory T cells

Nature Immunology

Volumn 17, Issue 5, 2016, Pages 556-564

  Apostolidis, Sokratis A ^a   Rodríguez Rodríguez, Noé ^a   Suárez Fueyo, Abel ^a   Dioufa, Nikolina ^a   Ozcan, Esra ^a   Crispín, José C ^a   Tsokos, Maria G ^a   Tsokos, George C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATASE; PHOSPHATASE PP2A; UNCLASSIFIED DRUG; CERAMIDE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PHOSPHOPROTEIN PHOSPHATASE 2; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; ANIMAL; AUTOIMMUNE DISEASE; C57BL MOUSE; CELL CULTURE; FEMALE; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNOBLOTTING; IMMUNOLOGY; JURKAT CELL LINE; KNOCKOUT MOUSE; LYMPHOPROLIFERATIVE DISEASE; MALE; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CELLS, CULTURED; CERAMIDES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; JURKAT CELLS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MULTIPROTEIN COMPLEXES; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TOR SERINE-THREONINE KINASES;

EID: 84961226881     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3390     Document Type: Article

References (55)

1. Starr, T.K., Jameson, S.C., Hogquist, K.A. Positive and negative selection of T cells. Annu. Rev. Immunol. 21, 139-176 (2003).
2. Josefowicz, S.Z., Lu, L.F., Rudensky, A.Y. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531-564 (2012).
3. Chi, H. Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 12, 325-338 (2012).
4. Lyon, M.F., Peters, J., Glenister, P.H., Ball, S., Wright, E. The scurfy mouse mutant has previously unrecognized hematological abnormalities and resembles Wiskott-Aldrich syndrome. Proc. Natl. Acad. Sci. USA 87, 2433-2437 (1990).
5. Bennett, C.L. et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27, 20-21 (2001).
6. Xu, Y. et al. Structure of the protein phosphatase 2A holoenzyme. Cell 127, 1239-1251 (2006).
7. Shi, Y. Serine/threonine phosphatases: mechanism through structure. Cell 139, 468-484 (2009).
8. Mumby, M. PP2A: unveiling a reluctant tumor suppressor. Cell 130, 21-24 (2007).
9. Sontag, J.M., Sontag, E. Protein phosphatase 2A dysfunction in Alzheimer's disease. Front. Mol. Neurosci. 7, 16 (2014).
10. Tsokos, G.C. Systemic lupus erythematosus. N. Engl. J. Med. 365, 2110-2121 (2011).
11. Katsiari, C.G., Kyttaris, V.C., Juang, Y.T., Tsokos, G.C. Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. J. Clin. Invest. 115, 3193-3204 (2005).
12. Xie, L. et al. Protein phosphatase 2A catalytic subunit α plays a MyD88-dependent, central role in the gene-specific regulation of endotoxin tolerance. Cell Rep. 3, 678-688 (2013).
13. Zhou, P. et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature 506, 52-57 (2014).
14. Long, L. et al. Recruitment of phosphatase PP2A by RACK1 adaptor protein deactivates transcription factor IRF3 and limits type I interferon signaling. Immunity 40, 515-529 (2014).
15. Stritesky, G.L., Jameson, S.C., Hogquist, K.A. Selection of self-reactive T cells in the thymus. Annu. Rev. Immunol. 30, 95-114 (2012).
16. Levine, A.G., Arvey, A., Jin, W., Rudensky, A.Y. Continuous requirement for the TCR in regulatory T cell function. Nat. Immunol. 15, 1070-1078 (2014).
17. Salomon, B. et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431-440 (2000).
18. Fontenot, J.D., Rasmussen, J.P., Gavin, M.A., Rudensky, A.Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6, 1142-1151 (2005).
19. Setoguchi, R., Hori, S., Takahashi, T., Sakaguchi, S. Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201, 723-735 (2005).
20. Delgoffe, G.M. et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12, 295-303 (2011).
21. Haxhinasto, S., Mathis, D., Benoist, C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J. Exp. Med. 205, 565-574 (2008).
22. Shrestha, S. et al. Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. Nat. Immunol. 16, 178-187 (2015).
23. Delgoffe, G.M. et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 501, 252-256 (2013).
24. Hombauer, H. et al. Generation of active protein phosphatase 2A is coupled to holoenzyme assembly. PLoS Biol. 5, e155 (2007).
25. Sents, W., Ivanova, E., Lambrecht, C., Haesen, D., Janssens, V. The biogenesis of active protein phosphatase 2A holoenzymes: a tightly regulated process creating phosphatase specificity. FEBS J. 280, 644-661 (2013).
26. Jiang, L. et al. Structural basis of protein phosphatase 2A stable latency. Nat. Commun. 4, 1699 (2013).
27. Haesen, D., Sents, W., Lemaire, K., Hoorne, Y., Janssens, V. The basic biology of PP2A in hematologic cells and malignancies. Front. Oncol. 4, 347 (2014).
28. Brunkow, M.E. et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27, 68-73 (2001).
29. Baharians, Z., Schönthal, A.H. Autoregulation of protein phosphatase type 2A expression. J. Biol. Chem. 273, 19019-19024 (1998).
30. Janssens, V., Longin, S., Goris, J. PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem. Sci. 33, 113-121 (2008).
31. Chen, J., Martin, B.L., Brautigan, D.L. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 257, 1261-1264 (1992).
32. Neviani, P. et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8, 355-368 (2005).
33. Trotta, R. et al. The PP2A inhibitor SET regulates natural killer cell IFN-γ production. J. Exp. Med. 204, 2397-2405 (2007).
34. Li, M., Makkinje, A., Damuni, Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J. Biol. Chem. 271, 11059-11062 (1996).
35. Dobrowsky, R.T., Kamibayashi, C., Mumby, M.C., Hannun, Y.A. Ceramide activates heterotrimeric protein phosphatase 2A. J. Biol. Chem. 268, 15523-15530 (1993).
36. Oaks, J., Ogretmen, B. Regulation of PP2A by sphingolipid metabolism and signaling. Front. Oncol. 4, 388 (2014).
37. Mukhopadhyay, A. et al. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J. 23, 751-763 (2009).
38. Feuerer, M., Hill, J.A., Mathis, D., Benoist, C. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat. Immunol. 10, 689-695 (2009).
39. Luberto, C., Hannun, Y.A. Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation. Does sphingomyelin synthase account for the putative phosphatidylcholine-specific phospholipase C? J. Biol. Chem. 273, 14550-14559 (1998).
40. Separovic, D. et al. Sphingomyelin synthase 1 suppresses ceramide production and apoptosis post-photodamage. Biochem. Biophys. Res. Commun. 358, 196-202 (2007).
41. Arvey, A. et al. Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells. Nat. Immunol. 15, 580-587 (2014).
42. Laplante, M., Sabatini, D.M. mTOR signaling in growth control and disease. Cell 149, 274-293 (2012).
43. Zeng, H. et al. mTORC1 couples immune signals and metabolic programming to establish Treg-cell function. Nature 499, 485-490 (2013).
44. Marin, T.M. et al. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J. Clin. Invest. 121, 1026-1043 (2011).
45. Liu, G., Yang, K., Burns, S., Shrestha, S., Chi, H. The S1P1-mTOR axis directs the reciprocal differentiation of TH1 and Treg cells. Nat. Immunol. 11, 1047-1056 (2010).
46. Battaglia, M., Stabilini, A., Roncarolo, M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105, 4743-4748 (2005).
47. Samstein, R.M. et al. Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification. Cell 151, 153-166 (2012).
48. Maceyka, M., Spiegel, S. Sphingolipid metabolites in inflammatory disease. Nature 510, 58-67 (2014).
49. Andjelković, M. et al. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc. Natl. Acad. Sci. USA 93, 5699-5704 (1996).
50. Huynh, A. et al. Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nat. Immunol. 16, 188-196 (2015).
51. Ruediger, R., Ruiz, J., Walter, G. Human cancer-associated mutations in the Aα subunit of protein phosphatase 2A increase lung cancer incidence in Aα knock-in and knockout mice. Mol. Cell. Biol. 31, 3832-3844 (2011).
52. Rubtsov, Y.P. et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28, 546-558 (2008).
53. Bielawski, J. et al. Comprehensive quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods Mol. Biol. 579, 443-467 (2009).
54. R Development Core Team. R: a language and environment for statistical computing (R Foundation for Statistical Computing, 2008).
55. Wu, Y. et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126, 375-387 (2006).